Skip to main content
. Author manuscript; available in PMC: 2021 Feb 12.
Published in final edited form as: Transfusion. 2014 Nov 5;55(4):709–718. doi: 10.1111/trf.12918

TABLE 4.

Rates of transfusion-related adverse reactions per 100,000 total units (full and aliquot) transfused,* by component type, collection method, irradiation, and leukoreduction as reported to the NHSN Hemovigilance Module, United States, 2010 to 2012

Transfused blood components Total adverse reactions§ Allergic FNHTR DSTR TACO Hypotensive DHTR TAD TRALI AHTR TTI
All components
 All adverse reactions 5136 (239.5) 2406 (112.2) 1853 (86.4) 321 (15.0) 196 (9.1) 136 (6.3) 90 (4.2) 72 (3.4) 26 (1.2) 24 (1.1) 12 (0.6)
 Severe, life-threatening, and fatal adverse reactions 376 (17.5) 172 (8.0) 18 (0.8) 3 (0.1) 72 (3.4) 34 (1.6) 17 (0.8) 17 (0.8) 22 (1.0) 12 (0.6) 9 (0.4)
RBCs
 All units 2519 (205.5) 657 (53.6) 1303 (106.3) 309 (25.2) 75 (6.1) 85 (6.9) 49 (4.0) 18 (1.5) 19 (1.6) 4 (0.3)
 Collection method
  Apheresis 253 (243.9) 63 (60.7) 130 (125.3) 28 (27.0) 11 (10.6) 17 (16.4) 4 (3.9) 0 (0) 0 (0) 0 (0)
  Whole blood derived 2236 (199.3) 590 (52.6) 1167 (104.0) 268 (23.9) 64 (5.7) 65 (5.8) 45 (4.0) 16 (1.4) 18 (1.6) 3 (0.3)
 Irradiation
  Irradiated 610 (200.2) 184 (60.4) 339 (111.3) 41 (13.5) 18 (5.9) 10 (3.3) 10 (3.3) 3 (1.0) 3 (1.0) 2 (0.7)
  Not irradiated 1902 (206.5) 471 (51.1) 964 (104.7) 264 (28.7) 57 (6.2) 74 (8.0) 39 (4.2) 15 (1.6) 16 (1.7) 2 (0.2)
 Leukoreduction
  Leukoreduced 2389 (205.1) 638 (54.8) 1225 (105.2) 296 (25.4) 71 (6.1) 72 (6.2) 47 (4.0) 18 (1.5) 18 (1.5) 4 (0.3)
  Not leukoreduced 127 (208.8) 19 (31.2) 78 (128.2) 12 (19.7) 4 (6.6) 11 (18.1) 2 (3.3) 0 (0) 1 (1.6) 0 (0)
PLTs
 All units 1659 (421.7) 1188 (302.0) 404 (102.7) 4 (1.0) 28 (7.1) 3 (0.8) 16 (4.1) 4 (1.0) 5 (1.3) 7 (1.8)
 Collection method
  Apheresis 1547 (537.6) 1134 (394.1) 358 (124.4) 3 (1.0) 25 (8.7) 3 (1.0) 12 (4.2) 3 (1.0) 4 (1.4) 5 (1.7)
  Whole blood derived 107 (101.3) 52 (49.2) 44 (41.7) 0 (0) 3 (2.8) 0 (0) 4 (3.8) 1 (0.9) 1 (0.9) 2 (1.9)
 Irradiation
  Irradiated 876 (289.6) 604 (199.7) 231 (76.4) 3 (1.0) 15 (5.0) 0 (0) 14 (4.6) 3 (1.0) 2 (0.7) 4 (1.3)
  Not irradiated 782 (860.3) 584 (642.4) 172 (189.2) 1 (1.1) 13 (14.3) 3 (3.3) 2 (2.2) 1 (1.1) 3 (3.3) 3 (3.3)
 Leukoreduction
  Leukoreduced 1643 (430.9) 1179 (309.2) 398 (104.4) 4 (1.0) 28 (7.3) 2 (0.5) 16 (4.2) 4 (1.0) 5 (1.3) 7 (1.8)
  Not leukoreduced 15 (124.5) 9 (74.7) 5 (41.5) 0 (0) 0 (0) 1 (8.3) 0 (0) 0 (0) 0 (0) 0 (0)
Plasma
 All units 511 (127.7) 423 (105.7) 58 (14.5) 0 (0) 23 (5.7) 0 (0) 4 (1.0) 3 (0.7) 0 (0) 0 (0)
 Collection method
  Apheresis 44 (145.7) 36 (119.2) 4 (13.2) 0 (0) 4 (13.2) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
  Whole blood derived 457 (123.5) 379 (102.4) 54 (14.6) 0 (0) 18 (4.9) 0 (0) 3 (0.8) 3 (0.8) 0 (0) 0 (0)
 Cryoprecipitate
  All units 7 (5.6) 6 (4.8) 1 (0.8) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
*

Rates are based on total components transfused as reported by included facilities for 2010-2012.

Data are reported as number (rate).

Adverse reactions that met definite or probable case definition and definite, probable, or possible imputability criteria as reported by 77 health care facilities included in this analysis.

§

Adverse reactions for which a specific component type was not reported (244 reactions) are included in rate calculations for all components.

Circulatory overload is not reported as due to a specific component type per NHSN Hemovigilance Module protocol.

AHTR = acute hemolytic transfusion reaction; DHTR = delayed hemolytic transfusion reaction; DSTR = delayed serologic transfusion reaction; FNHTR = febrile nonhemolytic transfusion reaction; TACO = transfusion-associated circulatory overload; TAD = transfusion-associated dyspnea; TRALI = transfusion-related acute lung injury; TTI = transfusion-transmitted infection.